These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23375736)

  • 1. Blood component recalls and market withdrawals: frequency, reasons, and management in the United States.
    Ramsey G
    Transfus Med Rev; 2013 Apr; 27(2):82-90. PubMed ID: 23375736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing recalls and withdrawals of blood components.
    Ramsey G
    Transfus Med Rev; 2004 Jan; 18(1):36-45. PubMed ID: 14689376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop.
    Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA
    Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood component recalls in the United States.
    Ramsey G; Sherman LA
    Transfusion; 1999 May; 39(5):473-8. PubMed ID: 10335996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Blood Product Market Withdrawals - A Single Institution's Process and Experience.
    Jug R; Bandarenko N; Poisson J
    Ann Clin Lab Sci; 2020 Jul; 50(4):536-540. PubMed ID: 32826252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood product recalls in the United States.
    McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
    Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AABB contributions to plasma safety.
    Triulzi DJ
    Transfusion; 2012 May; 52 Suppl 1():5S-8S. PubMed ID: 22578373
    [No Abstract]   [Full Text] [Related]  

  • 8. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States.
    Alqemlas I; Shankar S; Handagama W; Felse PA
    Blood Adv; 2020 Apr; 4(8):1780-1791. PubMed ID: 32343797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keeping transfusion blood safe.
    Rogoski RR
    MLO Med Lab Obs; 2010 Sep; 42(9):40, 43. PubMed ID: 20929175
    [No Abstract]   [Full Text] [Related]  

  • 11. Blood component recalls in the United States, 1998.
    Ramsey G; Sherman LA
    Transfusion; 2000 Feb; 40(2):253-4. PubMed ID: 10686012
    [No Abstract]   [Full Text] [Related]  

  • 12. Should the FDA mandate that autologous units drawn and transfused within a single institution be tested for markers of infectious disease?
    Perkins J; Kaminer L; Kruskall M; Cannon M; Uhl L; Dzik W; Silver H; O'Neill M; Popovsky M; King K; Ness P; AuBuchon J; Shapiro A; Yomtovian R; Petz LD
    Transfusion; 2000 Jun; 40(6):752-4. PubMed ID: 10865000
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood safety. The Food and Drug Administration's role.
    Gustafson M
    Arch Pathol Lab Med; 1999 Jun; 123(6):475-7. PubMed ID: 10383796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Time to introduce audit of transfusion treatment. Local transfusion committees should be established in Sweden].
    Schött U; Norda R; Ostlund I; Wikman A
    Lakartidningen; 2010 Dec 15-21; 107(50):3216-20. PubMed ID: 21294336
    [No Abstract]   [Full Text] [Related]  

  • 15. Postdonation information and blood component retrievals: realigning blood center and hospital actions based on risk assessment.
    Eder AF; Goldman M
    Transfus Med Rev; 2014 Oct; 28(4):226-34. PubMed ID: 25311469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of the practices of labile blood product distribution].
    Tardivel R
    Transfus Clin Biol; 2005 Jun; 12(2):177-9. PubMed ID: 15894509
    [No Abstract]   [Full Text] [Related]  

  • 17. Research opportunities in optimizing storage of red blood cell products.
    Wagner SJ; Glynn SA; Welniak LA;
    Transfusion; 2014 Feb; 54(2):483-94. PubMed ID: 23676138
    [No Abstract]   [Full Text] [Related]  

  • 18. Recalls of foods due to microbiological contamination classified by the U.S. Food and Drug Administration, fiscal years 2003 through 2011.
    Dey M; Mayo JA; Saville D; Wolyniak C; Klontz KC
    J Food Prot; 2013 Jun; 76(6):932-8. PubMed ID: 23726186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How we manage AB plasma inventory in the blood center and transfusion service.
    Yazer M; Eder AF; Land KJ
    Transfusion; 2013 Aug; 53(8):1627-33. PubMed ID: 23614505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012.
    Harvey AR; Basavaraju SV; Chung KW; Kuehnert MJ
    Transfusion; 2015 Apr; 55(4):709-18. PubMed ID: 25371300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.